Human brain natriuretic peptide,BNP ELISA Kit

Code CSB-E07970h
Size 96T,5×96T,10×96T
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
brain natriuretic peptide,BNP
Alternative Names
ANFB_HUMAN ELISA Kit; BNP ELISA Kit; BNP(1-32) ELISA Kit; BNP(5-29) ELISA Kit; BNP-32 ELISA Kit; Brain type natriuretic peptide ELISA Kit; Gamma brain natriuretic peptide ELISA Kit; Gamma-brain natriuretic peptide ELISA Kit; Natriuretic peptide precursor B ELISA Kit; nppb ELISA Kit; NT proBNP ELISA Kit
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, urine, tissue homogenates, cell culture supernates
Detection Range
93.75 pg/mL-6000 pg/mL
23.43 pg/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human BNP in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %86
Range %81-92
1:2Average %95
Range %90-105
1:4Average %95
Range %91-110
1:8Average %93
Range %86-98
The recovery of human BNP spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9690-100
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
60002.311 2.256 2.284 2.179
30001.905 1.876 1.891 1.786
15001.548 1.447 1.498 1.393
7501.102 1.059 1.081 0.976
3750.871 0.857 0.864 0.759
187.50.502 0.490 0.496 0.391
93.750.313 0.297 0.305 0.200
00.109 0.101 0.105  
Materials provided
  • A micro ELISA plate --- The 96-well plate has been pre-coated with an anti-human BNP antibody. This dismountable microplate can be divided into 12 x 8 strip plates.
  • Two vials lyophilized standard --- Dilute a bottle of the standard at dilution series, read the OD values, and then draw a standard curve.
  • One vial Biotin-labeled BNP antibody (100 x concentrate) (120 μl/bottle) ---Act as the detection antibody.
  • One vial HRP-avidin (100 x concentrate) (120 μl/bottle) --- Bind to the detection antibody and react with the TMB substrate to make the solution chromogenic.
  • One vial Biotin-antibody Diluent (15 ml/bottle) ---Dilute the Biotin-antibody.
  • One vial HRP-avidin Diluent (15 ml/bottle) ---Dilute the HRP-avidin solution.
  • One vial Sample Diluent (50 ml/bottle)---Dilute the sample to an appropriate concentration.
  • One vial Wash Buffer (25 x concentrate) (20 ml/bottle) --- Wash away unbound or free substances.
  • One vial TMB Substrate (10 ml/bottle) --- Act as the chromogenic agent. TMB interacts with HRP, eliciting the solution turns blue.
  • One vial Stop Solution (10 ml/bottle) --- Stop the color reaction. The solution color immediately turns from blue to yellow.
  • Four Adhesive Strips (For 96 wells) --- Cover the microplate when incubation.
  • An instruction manual
Materials not provided
  • A microplate reader capable of measuring absorbance at 450 nm, with the correction wavelength set at 540 nm or 570 nm.
  • An incubator that can provide stable incubation conditions up to 37°C±5°C.
  • Centrifuge
  • Vortex
  • Squirt bottle, manifold dispenser, or automated microplate washer
  • Absorbent paper for blotting the microtiter plate
  • 50-300ul multi-channel micropipette
  • Pipette tips
  • Single-channel micropipette with different ranges
  • 100ml and 500ml graduated cylinders
  • Deionized or distilled water
  • Timer
  • Test tubes for dilution
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Human BNP ELISA Kit was designed for the quantitative measurement of Human BNP protein in serum, urine, tissue homogenates, cell culture supernates. It is a Sandwich ELISA kit, its detection range is 93.75 pg/mL-6000 pg/mL and the sensitivity is 23.43 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Cardiac hormone that plays a key role in mediating cardio-renal homeostasis. May also function as a paracrine antifibrotic factor in the heart. Acts by specifically binding and stimulating NPR1 to produce cGMP, which in turn activates effector proteins that drive various biological responses. Involved in regulating the extracellular fluid volume and maintaining the fluid-electrolyte balance through natriuresis, diuresis, vasorelaxation, and inhibition of renin and aldosterone secretion. Binds the clearance receptor NPR3.; May affect cardio-renal homeostasis. Able to promote the production of cGMP although its potency is very low compared to brain natriuretic peptide 32.; May have a role in cardio-renal homeostasis. Able to promote the production of cGMP.
Gene References into Functions
  1. NT-BNP is elevated in fetal aortic stenosis. PMID: 29327361
  2. Combinative index (arterial lactate, NT-proBNP and CRP) could serve as a valuable predictor for the 28-day mortality rate in patients with sepsis. PMID: 30158031
  3. Patients diagnosed with portopulmonary hypertension (POPH) had significantly higher BNP levels in comparison with those patients without. In contrast, PELD/MELD scores showed an almost negligible correlation with the BNP level. Liver transplantation was successful in 3 asymptomatic biliary atresia patients with POPH who had high BNP levels despite the low PELD/MELD scores. PMID: 29733490
  4. NT-proBNP was associated with poor outcomes for patients with acute respiratory distress syndrome, and its level predicted mortality. PMID: 28322314
  5. Levels of N-terminal pro-brain-type natriuretic peptide increases in response to exercise in patients with pulmonary arterial hypertension. PMID: 29334941
  6. Admission NT-proBNP is an independent predictor for short- and long-term adverse events in Takotsubo syndrome patients. PMID: 29675571
  7. Report a weak correlation between B-type natriuretic peptide and within-visit blood pressure variability. PMID: 29604077
  8. Lung ultrasound, serum B-type natriuretic peptide levels, and echocardiography can be used for outcome prediction in patients with acute heart failure. PMID: 29532155
  9. Data suggest that intact FGF23 level in plasma is independent predictor of cardiovascular death in patients with heart failure and provides added value to standard of care, natriuretic peptide (NT-proBNP) plasma level, for risk estimation. This study was conducted in Belgium. (FGF23 = fibroblast growth factor 23; NT-proBNP = aminoterminal pro-B-type natriuretic peptide) PMID: 30205090
  10. Report decreased NT-proBNP levels in heart failure patients in contemporary heart failure management programs. PMID: 29656687
  11. NT-proBNP may have a role in myocardial conduction abnormalities in patients with diabetes mellitus PMID: 29121498
  12. recombinant human brain natriuretic peptide can regulate expression of IL-6, TNF-alpha, and IL-10 in lipopolysaccharide-activated RAW 264.7 cells. PMID: 29754152
  13. n elderly patients with symptoms of heart failure ST2 was not superior to NTproBNP to predict all cause or cardiovascular mortality. Furthermore, it is unclear if the combination of ST2 and NTproBNP will improve long-term prognostication beyond what is achieved by NTproBNP alone. PMID: 29355441
  14. current cutoffs for diagnosing HF for NT-proBNP and BNP have relatively low diagnostic concordance and correlation, particularly among patients with chronic kidney disease PMID: 30111510
  15. Elevated plasma NT-proBNP and KIM-1 in patients with stage 5 chronic kidney disease (CKD5) undergoing maintenance hemodialysis (HD) and HF (+) (heart failure)CKD5-HD patients suggest that natriuretic peptides and KIM-1 may contribute to the pathogenesis of HF in CKD5-HD patients. PMID: 28990414
  16. Increased levels of NT-proBNP seems to be a better biomarker of multidrug antihypertensive therapy requirement than CT-proAVP. PMID: 29190613
  17. Baseline NT-proBNP concentration was associated with short-term stroke among patients hospitalized with acute heart filure. Stroke risk assessment models should consider incorporation of NT-proBNP measurement. PMID: 28905172
  18. Suggest potential role for BNP as a protective endogenous factor against cerebral ischemia. PMID: 29203579
  19. In children with chronic kidney disease, BNP is an indicator of heart failure correlating with renal function parameters and left ventricular mass index. PMID: 29775443
  20. Data indicate that B-type natriuretic peptide (BNP) was outcome associated in acute heart failure patients. PMID: 28132515
  21. Combination of coronary artery calcium score and NT-proBNP could be used to identify a group of coronary artery disease patients where MPI could be averted with a high degree of diagnostic safety. PMID: 27005324
  22. NT-pro-BNP was not significantly different between subjects with 1-2 stenotic coronary arteries compared to those with 3 stenotic coronary arteries. PMID: 28845719
  23. Serum levels of ST2, IL-33 and BNP were independent risk factors for major adverse cardiovascular events in acute myocardial infarction after percutaneous coronary intervention. PMID: 28623858
  24. Circulating NT-proBNP levels are lower in overweight patients, even in those with diabetes, compared to controls. PMID: 28946871
  25. Report usefulness of point-of-care test for NT-proBNP in primary care for the diagnosis of heart failure. PMID: 29263170
  26. In-hospital mortality in patients with sepsis and low risk of sepsis-related organ failure was associated with NT-proBNP > 1,330 pg/ml. PMID: 28473224
  27. The results of the present study suggest the possible use of the molecular pathology of BNP for the determination of the terminal cardiac function in SCD and analysis of its death mechanism in forensic practice. PMID: 28765973
  28. In patients with a recent acute coronary syndrome and type 2 diabetes mellitus, BNP and NT-proBNP were powerful predictors of cardiovascular outcomes beyond heart failure and death, ie, were also predictive of MI and stroke. PMID: 28554908
  29. Data suggest that subjects with morbid obesity exhibit down-regulation of serum levels of BNP compared to control subjects. This study was conducted in Italy. PMID: 27426417
  30. Increased baseline values of BNP (and BigET-1) after acute myocardial infarction, were independently predictive of future cardiovascular events. PMID: 28284500
  31. Patients with acute exacerbation of COPD and elevated NT-pro-BNP levels had increased hospital length of stay and need for intensive care. PMID: 28458528
  32. BNP blood level is a biomarker for the the severity of hand-foot-mouth disease PMID: 28962547
  33. Plasma levels of NT-pro-BNP were significantly higher in hypertrophic cardiomyopathy (HCM) patients with more advanced disease. Elevated NT-pro-BNP not only reflects the diastolic impairment of the LV, but it might also be the result of cardiac ischemia in patients with HCM. PMID: 28336204
  34. Increased preoperative brain natriuretic peptide concentration was associated with risk of serious adverse events in pediatric cardiac surgery patients. PMID: 27919715
  35. NPPB SNPs were not associated with insulin resistance in older adults. PMID: 27101535
  36. Higher blood levels of NT-proBNP was associated with incident cognitive impairments. PMID: 27567834
  37. In people with Type 2 diabetes, high baseline B-type natriuretic peptide levels were significantly associated with future atrial fibrillation development. PMID: 26173591
  38. Plasma BNP levels were independently associated with functional outcomes 3 months after stroke onset in atrial fibrillation patients. PMID: 28253498
  39. Short-term follow-up BNP and percent change in BNP level are significant prognostic factors of all-cause mortality in hospitalized heart failure patients. PMID: 28774268
  40. NT-proBNP showed an incremental prognostic value for prediction of adverse outcomes when added to the clinical and echocardiographic parameters in patients with left ventricular dysfunction. PMID: 28349264
  41. BNP gene body hypermethylation is associated with the risk of rheumatic heart disease (RHD), and also influenced by the warfarin anticoagulant therapy of RHD patients after surgery, which could represent novel and promising targets for therapeutic development. PMID: 27920275
  42. IL-6 receptor blockade has an effect on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis PMID: 27744141
  43. An exercise-associated increase in hs-cTnT and NT-proBNP occurred in response to a 60-minute maximal swimming test that was independent of pubertal status/adolescent vs adults. The present data also suggests that baseline and postexercise hs-cTnT values are higher in male compared with female, with no sex differences in NT-proBNP values. PMID: 29173327
  44. An increase in NT-proBNP is a strong predictor of outcome in patients with left ventricular non-compaction cardiomyopathy. PMID: 28268080
  45. Brain Natriuretic Peptide levels increased as heart failure duration increased. PMID: 28268084
  46. In this hospitalized heart failure cohort, atrial fibrillation/flutter status did not influence post-discharge NT-proBNP trajectory. PMID: 27748006
  47. NT-proBNP and BNP levels were statistically higher in patients with heart failure and anemia compared to patients with heart failure and without anemia. PMID: 28587950
  48. The rs198389 G allele in the NPPB promoter is associated with elevated levels of NT-proBNP throughout adult life, reduced blood pressure, hypertension and cardiovascular mortality, and increased lifespan. PMID: 28341776
  49. Atrial fibrillation risk discrimination was not significantly improved by the addition of NT-proBNP levels to the Framingham AF risk model. PMID: 27194537
  50. Combination of high serum BNP levels, along with high soluble AXL had greater predictive value for heart failure than BNP alone. PMID: 27718443

Show More

Hide All

Subcellular Location
[NT-proBNP]: Secreted.; [proBNP(3-108)]: Secreted.; [Brain natriuretic peptide 32]: Secreted.; [BNP(3-32)]: Secreted.
Protein Families
Natriuretic peptide family
Tissue Specificity
[Brain natriuretic peptide 32]: Detected in the cardiac atria (at protein level). Detected in the kidney distal tubular cells (at protein level).
Database Links

HGNC: 7940

OMIM: 600295

KEGG: hsa:4879

STRING: 9606.ENSP00000365651

UniGene: Hs.219140

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1